<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546362</url>
  </required_header>
  <id_info>
    <org_study_id>50212</org_study_id>
    <nct_id>NCT02546362</nct_id>
  </id_info>
  <brief_title>CEFALY® Device in the Treatment of Patients With Fibromyalgia</brief_title>
  <official_title>A Single Center, Pilot, Open Trial of the CEFALY® Device in the Treatment of Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cefaly Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cefaly Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pilot open trial is to investigate the efficacy and safety of e-TNS
      with the Cefaly(R) device in fibromyalgia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pain intensity between baseline and 12 weeks endpoint</measure>
    <time_frame>Baseline and 12 weeks endpoint</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fibromyalgia Impact Questionnaire-revised (FIQR) total score between baseline and 12 weeks endpoint</measure>
    <time_frame>Baseline and 12 weeks endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean pain intensity between baseline and 4 weeks visit</measure>
    <time_frame>Baseline and 4 weeks visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FIQR between baseline and 4 weeks visit</measure>
    <time_frame>Baseline and 4 weeks visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) at 4 weeks visit and at 12 weeks endpoint</measure>
    <time_frame>4 weeks visit and at 12 weeks endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D-3L between baseline and 4 weeks visit; and between baseline and 12 weeks endpoint</measure>
    <time_frame>Baseline and 4 weeks visit; baseline and 12 weeks endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcomes Measurement Information System (PROMIS) measures for depression, fatigue and sleep between baseline and 4 weeks visit; and between baseline and 12 weeks endpoint</measure>
    <time_frame>Baseline and 4 weeks visit; baseline and 12 weeks endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multiple Ability Self-report Questionnaire (MASQ) between baseline and 4 weeks visit; and between baseline and 12 weeks endpoint</measure>
    <time_frame>Baseline and 4 weeks visit; baseline and 12 weeks endpoint</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>FM30 (≥30% responder rate)</measure>
    <time_frame>12 weeks endpoint</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>FM20 (≥20% responder rate)</measure>
    <time_frame>12 weeks endpoint</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cefaly</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged from18 to 65 years

          2. Diagnosed with FM according to the 2010 ACR Preliminary Diagnostic Criteria for
             Fibromyalgia

          3. Having a minimum pain score of at least 4 on the 0-10 FIQR pain scale at screening and
             baseline

        Exclusion Criteria:

          1. Women: Pregnant, lactating or &lt;6 months post partum

          2. Episodic or Chronic Migraine according to the diagnostic criteria listed in ICHD-III
             beta (2013) section 1, migraine 1, having two or more attacks per month.

          3. Change in any medication acting on the central nervous system (CNS) within 28 days
             before start of the study or during the study

          4. Severe depression i.e. having a Beck Depression Inventory-Fast Screen (BDI-FS) score
             &gt;12

          5. Botox injection within 4 months before baseline or during the study.

          6. Psychiatric disorders that could interfere with study participation: bipolar disorder,
             psychotic disorders and dementia.

          7. Suicidal behavior and/or ideation i.e. having a Columbia Suicide Severity Rating Scale
             (C-SSRS) score ≥ 4 during the preceding 2 years

          8. Patients currently taking any opioid medication

          9. Patients currently taking medically prescribed marijuana

         10. Current or history during the preceding year of alcohol or substance abuse including
             marijuana

         11. Intolerance to supraorbital neurostimulation that makes the treatment not applicable
             (test of nociceptive threshold with specific Cefaly program)

         12. Widespread rheumatic diseases (other than FM), evidence of inflammatory rheumatic
             disease

         13. Any unstable medical condition in the judgment of the investigator that would
             interfere with study participation or study assessments.

         14. Implanted active metal or electrical devices in the head

         15. Cardiac pacemaker or implanted or wearable defibrillator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lesley M. Arnold</last_name>
    <email>ARNOLDLM@UCMAIL.UC.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley M. Arnold</last_name>
      <email>ARNOLDLM@UCMAIL.UC.EDU</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

